Page 3 - மருந்துகள் தரநிலை கட்டுப்பாடு ஆர்கநைஸேஶந் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from மருந்துகள் தரநிலை கட்டுப்பாடு ஆர்கநைஸேஶந். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In மருந்துகள் தரநிலை கட்டுப்பாடு ஆர்கநைஸேஶந் Today - Breaking & Trending Today

DCGI approves anti-Covid drug developed by DRDO for emergency use - Coronavirus Outbreak News

UPDATED: May 8, 2021 16:19 IST
An anti-Covid-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) has been developed by DRDO in collaboration with Dr Reddy’s Laboratories, Hyderabad. (Photo: India Today/Manjeet Negi)
The Drugs Controller General of India (DCGI) has approved the emergency use of drug 2-deoxy-D-glucose (2-DG) as an adjunct therapy in moderate to severe Covid-19 patients.
The Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), has developed the drug, in collaboration with Dr Reddy’s Laboratories, Hyderabad.
Clinical trial results have shown that this molecule helps in faster recovery of hospitalized patients and reduces supplemental oxygen dependence. Being a generic molecule and analogue of glucose, it can be easily produced and made available in plenty. Higher proportion of patients treated with 2-DG showed RT-PCR negative conversion in Covid patients, DRDO said i ....

Andhra Pradesh , Tamil Nadu , Zydus Cadila Covid , Sharvil Patel , Centre For Cellular , Institute Of Nuclear Medicine , Central Drugs Standard Control Organization , Development Organisation , Defence Research , Drugs Controller General , Nuclear Medicine , Allied Sciences , Molecular Biology , Drugs Standard Control Organization , Bharat Biotech , West Bengal , ஆந்திரா பிரதேஷ் , தமிழ் நாடு , ஷார்வில் படேல் , மையம் க்கு செல்லுலார் , நிறுவனம் ஆஃப் அணு மருந்து , மைய மருந்துகள் தரநிலை கட்டுப்பாடு ஆர்கநைஸேஶந் , வளர்ச்சி ஆர்கநைஸேஶந் , பாதுகாப்பு ஆராய்ச்சி , மருந்துகள் கட்டுப்படுத்தி ஜநரல் , அணு மருந்து ,

DRDO's Anti-Covid Drug Gets DCGI's Nod For Emergency Use

DRDO s Anti-Covid Drug Gets DCGI s Nod For Emergency Use
The drug is expected to save precious lives due to the mechanism of operation of the drug in infected cells. This also reduces the hospital stay of COVID-19 patients, the defence ministry said.
The drug comes in powder form in a sachet and is taken orally by dissolving it in water. (Representational image.)
Outlook Web Bureau
2021-05-08T16:46:22+05:30
DRDO s Anti-Covid Drug Gets DCGI s Nod For Emergency Use
outlookindia.com
2021-05-08T16:50:27+05:30
Also read
The Drugs Controller General of India (DCGI) on Saturday approved the emergency use of an anti-Covid oral drug developed by the DRDO that can be used in treatment of moderate to severe Covid patients. ....

Uttar Pradesh , Andhra Pradesh , Tamil Nadu , Narendra Modi , Centre For Cellular , Institute Of Nuclear Medicine , Development Organisation , Central Drugs Standard Control Organisation , Defence Research , Drugs Controller General , Nuclear Medicine , Allied Sciences , Prime Minister Narendra Modi , Molecular Biology , Drugs Standard Control Organisation , West Bengal , உத்தர் பிரதேஷ் , ஆந்திரா பிரதேஷ் , தமிழ் நாடு , நரேந்திர மோடி , மையம் க்கு செல்லுலார் , நிறுவனம் ஆஃப் அணு மருந்து , வளர்ச்சி ஆர்கநைஸேஶந் , மைய மருந்துகள் தரநிலை கட்டுப்பாடு ஆர்கநைஸேஶந் , பாதுகாப்பு ஆராய்ச்சி , மருந்துகள் கட்டுப்படுத்தி ஜநரல் ,

DRDO's anti-COVID drug approved for emergency use- Business News

DRDO s anti-COVID drug approved for emergency use
An anti-COVID-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) has been developed by DRDO in collaboration with Dr Reddy s Laboratories, Hyderabad
BusinessToday.In | May 8, 2021 | Updated 16:22 IST
The Drugs Controller General of India (DCGI) has approved teh emergency use of drug 2-deoxy-D-glucose (2-DG) developed by DRDO
The Drugs Controller General of India (DCGI) on Saturday gave approval to the anti-COVID drug developed by DRDO (Defence Research and Development Organisation) for emergency use.
The drug, 2-deoxy-D-glucose (2-DG), to treat coronavirus patients has been developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddy s Laboratories, Hyderabad. ....

Andhra Pradesh , Institute Of Nuclear Medicine , Central Drugs Standard Control Organization , Development Organisation , Defence Research , Drugs Controller General , Nuclear Medicine , Allied Sciences , Molecular Biology , Drugs Standard Control Organization , ஆந்திரா பிரதேஷ் , நிறுவனம் ஆஃப் அணு மருந்து , மைய மருந்துகள் தரநிலை கட்டுப்பாடு ஆர்கநைஸேஶந் , வளர்ச்சி ஆர்கநைஸேஶந் , பாதுகாப்பு ஆராய்ச்சி , மருந்துகள் கட்டுப்படுத்தி ஜநரல் , அணு மருந்து , கூட்டணி அறிவியல் , மூலக்கூறு உயிரியல் , மருந்துகள் தரநிலை கட்டுப்பாடு ஆர்கநைஸேஶந் ,

DRDO's anti-COVID drug reducing oxygen dependence approved for emergency use

DRDO s anti-COVID drug reducing oxygen dependence approved for emergency use
Clinical trial results have shown that this molecule helps in faster recovery of hospitalized patients and reduces supplemental oxygen dependence.
Share Via Email
| A+A A-
By Express News Service
NEW DELHI: The Drugs Controller General of India (DGCI) has granted emergency use approval to an anti-Covid drug 2-deoxy-D-glucose (2-DG) developed by the Defence Research and Development Organisation(DRDO) lab. This after a three-phase clinical trial of the drug had shown a faster recovery of hospitalised patients.
The Ministry of Defence on Saturday informed that Clinical trial results have shown that this molecule helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence. A higher proportion of patients treated with 2-DG showed RT-PCR negative conversion in COVID patients. The drug will be of immense benefit to the people suffering from C ....

Uttar Pradesh , Andhra Pradesh , Tamil Nadu , Ministry Of Defence On , Centre For Cellular , News Service , Institute Of Nuclear Medicine , Central Drugs Standard Control Organization , Development Organisation , Defence Research , Express News , Drugs Controller General , Nuclear Medicine , Allied Sciences , Molecular Biology , Drugs Standard Control Organization , West Bengal , உத்தர் பிரதேஷ் , ஆந்திரா பிரதேஷ் , தமிழ் நாடு , அமைச்சகம் ஆஃப் பாதுகாப்பு ஆன் , மையம் க்கு செல்லுலார் , செய்தி சேவை , நிறுவனம் ஆஃப் அணு மருந்து , மைய மருந்துகள் தரநிலை கட்டுப்பாடு ஆர்கநைஸேஶந் , வளர்ச்சி ஆர்கநைஸேஶந் ,

DCGI approves DRDO-made anti-Covid drug for emergency use

An anti-COVID oral drug developed by the DRDO has been approved by the Drugs Controller General of India (DCGI) for emergency use as an adjunct therapy in moderate to severe coronavirus patients, the defence ministry said on Saturday.
Clinical trials of the drug 2-deoxy-D-glucose (2-DG) showed that it helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence, it said.
The approval to the drug has come at a time when India has been grappling with a record-breaking wave of coronavirus pandemic that has stretched the country s healthcare infrastructure to its limit.
In the ongoing second COVID-19 wave, a large number of patients are facing severe oxygen dependency and need hospitalisation. ....

Uttar Pradesh , Andhra Pradesh , Tamil Nadu , Narendra Modi , Centre For Cellular , Institute Of Nuclear Medicine , Development Organisation , Central Drugs Standard Control Organisation , Defence Research , Drugs Controller General , Nuclear Medicine , Allied Sciences , Prime Minister Narendra Modi , Molecular Biology , Drugs Standard Control Organisation , West Bengal , உத்தர் பிரதேஷ் , ஆந்திரா பிரதேஷ் , தமிழ் நாடு , நரேந்திர மோடி , மையம் க்கு செல்லுலார் , நிறுவனம் ஆஃப் அணு மருந்து , வளர்ச்சி ஆர்கநைஸேஶந் , மைய மருந்துகள் தரநிலை கட்டுப்பாடு ஆர்கநைஸேஶந் , பாதுகாப்பு ஆராய்ச்சி , மருந்துகள் கட்டுப்படுத்தி ஜநரல் ,